Esmolol improves sepsis outcomes through cardiovascular and immune modulation.

ABSTRACT:

Background

Sepsis poses significant mortality risks. Esmolol, a β1-adrenergic blocker, may improve outcomes through cardiovascular and immune modulation. This study aims to evaluate the effects of Esmolol on survival rates, inflammatory markers, and immune function in sepsis patients.

Methods

In this retrospective observational study, data from 268 sepsis patients were reviewed, and 125 met the inclusion criteria. These patients were divided into Esmolol and control groups. Data were collected from electronic health records, including survival rates, inflammatory markers (IL-6, PCT), and immune function markers (CD4⁺ and CD8⁺ T-cell counts). Statistical analyses included multivariate regression, Kaplan-Meier survival analysis, and Generalized Estimating

SUBMITTER: Jing D 

PROVIDER: S-EPMC12104586 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature